ICON Public (NASDAQ:ICLR) Issues FY 2024 Earnings Guidance

ICON Public (NASDAQ:ICLR) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 13.900-14.100 for the period, compared to the consensus EPS estimate of 15.060. The company issued revenue guidance of $8.3 billion-$8.3 billion, compared to the consensus revenue estimate of $8.5 billion. ICON Public also updated its FY24 guidance to $13.90-14.10 EPS.

ICON Public Trading Down 21.0 %

Shares of ICLR traded down $59.03 during trading hours on Thursday, hitting $221.73. 6,190,963 shares of the stock traded hands, compared to its average volume of 611,493. The business has a fifty day moving average of $301.78 and a 200-day moving average of $311.59. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $18.29 billion, a PE ratio of 28.72, a price-to-earnings-growth ratio of 1.35 and a beta of 1.22. ICON Public has a 1-year low of $220.51 and a 1-year high of $347.72.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing the consensus estimate of $3.72 by ($0.37). The business had revenue of $2.03 billion for the quarter, compared to the consensus estimate of $2.13 billion. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The business’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.10 EPS. Analysts expect that ICON Public will post 14.54 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Barclays lowered their target price on shares of ICON Public from $350.00 to $330.00 and set an “overweight” rating for the company in a research note on Tuesday, October 15th. Leerink Partnrs raised ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. Robert W. Baird cut ICON Public from an “outperform” rating to a “neutral” rating and set a $340.00 target price for the company. in a research note on Thursday. Truist Financial decreased their price objective on ICON Public from $383.00 to $363.00 and set a “buy” rating for the company in a research report on Monday, October 14th. Finally, StockNews.com lowered shares of ICON Public from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Three research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, ICON Public has a consensus rating of “Moderate Buy” and a consensus target price of $346.09.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.